$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[미국특허] Compositions for treating amyloid associated diseases 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-031/405
출원번호 UP-0660522 (2005-08-18)
등록번호 US-7732479 (2010-06-29)
국제출원번호 PCT/IL2005/000902 (2005-08-18)
§371/§102 date 20071010 (20071010)
국제공개번호 WO06/018850 (2006-02-23)
발명자 / 주소
  • Gazit, Ehud
  • Cohen, Tomer
출원인 / 주소
  • Tel Aviv University Future Technology Development L.P.
인용정보 피인용 횟수 : 15  인용 특허 : 50

초록

Indole derivatives, compositions including same, and methods utilizing same for the treatment of amyloid associated diseases, such as type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis, and prion-related encephalopathies are provided.

대표청구항

What is claimed is: 1. A method of treating Alzheimer's disease in a subject, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a compound selected from the group consisting of 3-hydroxyindole and 4-hydroxyindole and thereby treating the Alzheim

이 특허에 인용된 특허 (50) 인용/피인용 타임라인 분석

  1. Rubenstein Kenneth Edward (Palo Alto CA) Leute Richard K. (Sunnyvale CA), Antibody steric hindrance immunoassay with two antibodies.
  2. Iversen, Patrick L., Antisense antibacterial method and composition.
  3. Williams, Roger O.; Van Tuyl, Michael; Forbush, Michael, Apparatus and method for droplet steering.
  4. Yufei Gao ; Jun Liu, Carbon nanotubes on a substrate.
  5. Kawasaki Glenn H. (Seattle WA), Cell-free synthesis and isolation of novel genes and polypeptides.
  6. Kawasaki Glenn H. (Seattle WA), Cell-free synthesis and isolation of novel genes and polypeptides.
  7. Haber Edgar (Weston MA), Composition and method for determining the size and location of myocardial infarcts.
  8. Ghadiri, Reza M., Cyclic peptide tube.
  9. Fukuda Tsunehiko,JPX ; Fujisawa Yukio,JPX ; Watanabe Hiroyuki,JPX, Cysteine protease inhibitor.
  10. Steiner Solomon (Mt. Kisco NY) Rosen Robert (Rochester NY), Delivery systems for pharmacological agents encapsulated with proteinoids.
  11. Yanai Makoto,JPX ; Suzuki Masashi,JPX ; Oshida Norio,JPX ; Kawamura Koji,JPX ; Hiramoto Shigeru,JPX ; Yasuda Orie,JPX ; Kinoshita Nobuhiro,JPX ; Shingai Akiko,JPX ; Takasu Masako,JPX, Depsipeptides and drugs containing the same as the active ingredient.
  12. Berger Dieter (Viernheim DEX) Frey Gnter (Ludwigshafen DEX) Kuhr Manfred (Mannheim DEX) Werner Wolfgang (Mannheim DEX), Diagnostic agents for the detection of leukocytes in body fluids.
  13. Joyce Gerald F. ; Breaker Ronald R., Enzymatic DNA molecules.
  14. Pollak Alfred (Toronto CAX) Kirby Robert A. (Acton CAX) Dunn-Dufault Robert (Bramalea CAX), Hydrazino-type radionuclide chelators having an N3S configuration.
  15. Fowlkes, Dana M.; Kay, Brian K.; Frelinger, Jeffrey A.; Hyde-Deruyscher, Robin Parish, Identification of drug complementary combinatorial libraries.
  16. Batcho Andrew David (Belleville NJ) Leimgruber Willy (Montclair NJ), Intermediates for indoles.
  17. Woodle Martin C. (Menlo Park CA) Martin Francis J. (San Francisco CA) Yau-Young Annie (Los Altos CA) Redemann Carl T. (Walnut Creek CA), Liposomes with enhanced circulation time.
  18. Kogiso, Masaki; Shimizu, Toshimi, Metalic nanowire and process for producing the same.
  19. Chang Robert P. H., Method of encapsulating a material in a carbon nanotube.
  20. Weiner David B. (Merion Station PA) Ugen Kenneth E. (Philadelphia PA) Williams William V. (Havertown PA), Methods and compositions for diagnosing and treating certain HIV infected patients.
  21. Gold Larry (Boulder CO) Tuerk Craig (Boulder CO), Methods for identifying nucleic acid ligands.
  22. Gold Larry (Boulder CO) Tuerk Craig (Boulder CO), Methods of producing nucleic acid ligands.
  23. Findeis Mark A. ; Gefter Malcolm L. ; Musso Gary ; Signer Ethan R. ; Wakefield James ; Molineaux Susan ; Chin Joseph ; Lee Jung-Ja ; Kelley Michael ; Komar-Panicucci Sonja ; Arico-Muendel Christopher, Modulators of .beta.-amyloid peptide aggregation comprising D-amino acids.
  24. Gold Larry (Boulder CO) Tuerk Craig (Boulder CO), Nucleic acid ligands.
  25. Afroditi Kapurniotu DE; Jurgen Bernhagen DE; Herwig Brunner DE, Peptides used as agonists and/or inhibitors of amyloid formation and cytotoxicity and also for use in alzheimer's disease, in type II diabetes mellitus and in spongiform encephalophathies.
  26. Takle, Garry B.; Goldberg, Allan R.; George, Shaji T., Phenotypic conversion of cells mediated by external guide sequences.
  27. Kihara Naoko (Matsudo JPX) Yuasa Fumihiko (Tokyo JPX) Ushirogouchi Tohru (Yokohama JPX) Tada Tsukasa (Tokyo JPX) Sasaki Osamu (Sagamihara JPX) Naito Takuya (Tokyo JPX) Saito Satoshi (Yokohama JPX), Potosensitive composition and method of forming a pattern using the same.
  28. Mullis Kary B. (Kensington CA), Process for amplifying nucleic acid sequences.
  29. Bommarius Andreas,DEX ; Drauz Karlheinz,DEX ; Eichhorn Uwe,DEX ; Jakubke Hans-Dieter,DEX ; Kottenhahn Matthias,DEX, Process for preparing peptides and N-carbamoyl-protected peptides.
  30. Fischer Andreas (Bonn DEX) Schwarz Alexander (Rehovot ILX) Wandrey Christian (Juelich DEX) Knaup Guenter (Bruchkoebel DEX) Bommarius Andreas (Frankfurt DEX) Drauz Karl-Heinz (Freigericht DEX), Process for the enzymatic preparation of protected and unprotected di- and oligopeptides in aqueous solutions.
  31. Surani Azim M. (Cambridge GB3) Neuberger Michael S. (Cambridge GB3) Bruggemann Marianne (Cambridge GB3), Production of antibodies from transgenic animals.
  32. Woolfson,Derek N.; Walshaw,John; Pandya,Maya J.; Colyer,John, Protein structures and protein fibres.
  33. Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Ransgenic non-human animals for producing heterologous antibodies.
  34. Comis Alfio,AUX ; Tyler Margaret Isabel,AUX ; Fischer Peter,NOX, Retro-, inverso- and retro-inverso synthetic peptide analogues.
  35. Ladner Robert C. (Ijamsville MD) Bird Robert E. (Rockville MD) Hardman Karl (Chevy Chase MD), Single polypeptide chain binding molecules.
  36. Capps David B. (Ann Arbor MI), Substituted 1-amino-4-nitro-acridinones and methods of treating bacterial infections and leukemia with them.
  37. Gold Larry (Boulder CO) Ringquist Steven (Boulder CO), Systematic evolution of ligands by exponential enrichment: Solution SELEX.
  38. Biesecker Greg (Boulder CO) Jayasena Sumedha D. (Boulder CO) Gold Larry (Boulder CO) Smith Drew (Boulder CO) Kirschenheuter Gary P. (Arvada CO), Systematic evolution of ligands by exponential enrichment: blended SELEX.
  39. Gold Larry ; Eaton Bruce ; Smith Drew ; Wecker Matthew ; Jensen Kirk, Systematic evolution of ligands by exponential enrichment: chemi-SELEX.
  40. Burke Donald (Boulder CO) Tarasow Ted (Boulder CO) Eaton Bruce E. (Boulder CO) Gold Larry (Boulder CO), Systematic evolution of ligands by exponential enrichment: chimeric selex.
  41. Setterstrom Jean A. ; Van Hamont John E. ; Reid Robert H. ; Jacob Elliot ; Jeyanthi Ramasubbu ; Boedeker Edgar C. ; McQueen Charles E. ; Jarboe Daniel L. ; Cassels Frederick ; Brown William ; Thies C, Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix.
  42. Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies.
  43. Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
  44. Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
  45. Lonberg Nils (Redwood City CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals for producing heterologous antibodies.
  46. McHugh John E. (5139 Balboa Blvd. ; Ste. 1 Encino CA 91316) ..UC: 514/470 514/568, Treatment of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV infections and Acquired Immunodeficiency Syndroms (A.
  47. Politi Vincenzo (Rome ITX) De Luca Giovanna (Rome ITX) Di Stazio Giovanni (Rome ITX) Materazzi Mario (Rome ITX), Tryptophane and 3-indolepyruvic acid, methods of production therefor.
  48. Goldenberg Milton D. (11837 Gainsborough Rd. Potomac MD 20854), Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers.
  49. Eek, Arne; Raud, Johan, Use of compounds as antibacterial agents.
  50. Soto-Jara, Claudio, β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide.

이 특허를 인용한 특허 (15) 인용/피인용 타임라인 분석

  1. Gazit, Ehud; Amir, Yaniv; Buzhansky, Ludmila; Abel, Ulrich; Frydman-Marom, Anat, Dipeptide analogs for treating conditions associated with amyloid fibril formation.
  2. Gazit, Ehud; Amir, Yaniv; Buzhansky, Ludmila; Abel, Ulrich; Frydman-Marom, Anat, Dipeptide analogs for treating conditions associated with amyloid fibril formation.
  3. Gazit, Ehud, Method of screening for compounds that disaggregate amyloid aggregates.
  4. Gazit, Ehud, Peptides and methods using same for diagnosis and treatment of amyloid-associated disease.
  5. Gazit, Ehud, Peptides and methods using same for diagnosis and treatment of amyloid-associated disease.
  6. Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W., Use of NK-1 receptor antagonist serlopitant in pruritus.
  7. Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W., Use of NK-1 receptor antagonist serlopitant in pruritus.
  8. Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W., Use of NK-1 receptor antagonist serlopitant in pruritus.
  9. Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W., Use of NK-1 receptor antagonist serlopitant in pruritus.
  10. Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W., Use of NK-1 receptor antagonists in pruritus.
  11. Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W., Use of NK-1 receptor antagonists in pruritus.
  12. Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W., Use of NK-1 receptor antagonists in pruritus.
  13. Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W., Use of NK-1 receptor antagonists in pruritus.
  14. Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W., Use of NK-1 receptor antagonists in pruritus.
  15. Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W., Use of NK-1 receptor antagonists in pruritus.

활용도 분석정보

상세보기
다운로드
내보내기

활용도 Top5 특허

해당 특허가 속한 카테고리에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로